Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab

Figures & data

Table 1 Outcome parameters from studies on adalimumab in ulcerative colitis

Study (references)	Study type	Number of patients	Induction of clinical response/remission (%)	Maintenance of clinical response/remission (%)	Steroid sparing (%)	Mucosal healing (%)	Colectomy (%)
ULTRA 1^Citation20	RCT	390	Week 8: 54.6%/18.5%	–	–	Week 8: 46.9%	–
ULTRA 2^Citation21	RCT	494	Week 8: 50.4%/16.5%	Week 52: 34.6%/17.3%	37.8%	Week 8: 41.1% Week 52: 25%	–
Oussalah et al^Citation27	OL	13	–	42 weeks mean FU: 38.5% clinical benefit	–	–	46.2%
Afif et al^Citation28	OL	20	Week 8: 25%/5%	Week 24: 50%/25%	58%	–	–
Hudis et al^Citation29	RS	9	–	–	56%	–	–
Gies et al^Citation30	OL	25	Week 14: 80%/–	54.5 weeks median FU: 70%/–	100%	–	8%
Taxonera et al^Citation31	RS	30	Week 12: 60%/26.7%	48 weeks median FU: 50%/–	68%	–	20%
Ferrante et al^Citation33	RS	50	Week 4: 68%/–	23 months median FU: 52%/–	–	–	20%
McDermott et al^Citation32	RS	23	–	23 months median FU: 35% clinical benefit	–
García-Bosch et al^Citation34	RS	48	Week 12: 70.8%/50%	Week 54: 35%/30%	–	–	22.9%
Armuzzi et al^Citation35	RS	88	Week 12: –/28.4%	week 54: –/43.2%	56.7%	26.3%	25%

Abbreviations: RCT, randomized controlled trial; OL, open-label study; RS, retrospective study; FU, follow-up.

Reinisch W Sandborn WJ Hommes DW Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial Gut 2011 60 6 780 787 21209123

 PubMed Web of Science ®Google Scholar

Sandborn WJ van Assche G Reinisch W Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 2012 142 2 257 265 22062358

 PubMed Web of Science ®Google Scholar

Oussalah A Laclotte C Chevaux JB Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience Aliment Pharmacol Ther 2008 28 8 966 972 18652603

 PubMed Web of Science ®Google Scholar

AFC W Leighton JA Hanauer SB Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab Inflamm Bowel Dis 2009 15 9 1302 1307 19408340

 PubMed Web of Science ®Google Scholar

Hudis N Rajca B Polyak S Zeilman CJ Valentine JF The outcome of active ulcerative colitis treated with adalimumab Gastroenterology 2009 136 5 Suppl 1 A661

 Web of Science ®Google Scholar

Gies N Kroeker KI Wong K Fedorak RN Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort Aliment Pharmacol Ther 2010 32 4 522 528 20500733

 PubMed Web of Science ®Google Scholar

Taxonera C Estellés J Fernández-Blanco I Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab Aliment Pharmacol Ther 2011 33 3 340 348 21133961

 PubMed Web of Science ®Google Scholar

Ferrante M Karmiris K Compernolle G Efficacy of adalimumab in patients with ulcerative colitis: restoration of serum levels after dose escalation results in a better long-term outcome Gut 2011 60 Suppl 3 A72

 Google Scholar

McDermott E Murphy S Keegan D O’Donoghue D Mulcahy H Doherty G Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis J Crohns Colitis 2013 7 2 150 153 22520592

 PubMed Web of Science ®Google Scholar

García-Bosch O Gisbert JP Canas-Ventura A Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome J Crohns Colitis 2012 Epub 11 8 2012

 Web of Science ®Google Scholar

Armuzzi A Biancone L Daperno M Adalimumab in active ulcerative colitis: a “real-life” observational study Dig Liver Dis 2013

 Google Scholar